Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Kelp detritus: Unutilized productivity or an unacknowledged trophic resource?

The Science of the total environment·2022

Same author

Impact of peer support on inpatient and outpatient payments among people with Type 2 diabetes: a prospective cohort study.

Diabetic medicine : a journal of the British Diabetic Association·2018

Same author

SMi'S 4th Annual Orphan Drugs and Rare Diseases Conference (October 19-20, 2015--London, UK).

Drugs of today (Barcelona, Spain : 1998)·2015

Same author

Protein farnesyltransferase and adenosine receptors.

IDrugs : the investigational drugs journal·2008

Same author

Mitigation assessment of vegetated drainage ditches for collecting irrigation runoff in California.

Journal of environmental quality·2008

Same author

Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy.

The Journal of thoracic and cardiovascular surgery·2005

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

Search research articles

Related Experiment Videos

Anticoagulation strategies.

¹Current Drugs Limited, Middlesex House, 34-42 Cleveland Street, London, W1P 6LB, UK. peterro@cursci.co.uk

Idrugs : the Investigational Drugs Journal

|May 10, 2008

Summary

This summary is machine-generated.

New anticoagulation strategies targeting thrombin and Factor Xa are needed due to limitations of current drugs like warfarin. Advances in novel anticoagulant therapies were presented, addressing issues like bioavailability and safety.

Related Experiment Videos

Area of Science:

Pharmacology
Biochemistry
Internal Medicine

Background:

Classical anticoagulants like warfarin have limitations including poor oral bioavailability, lack of selectivity, short half-life, bleeding risk, and significant peak-to-trough variations.
Current parenteral anticoagulants such as hirudin, while effective thrombin inhibitors, are not suitable for oral administration.

Purpose of the Study:

To review recent advances in anticoagulation strategies focusing on novel thrombin and Factor Xa inhibitors.
To highlight the need for improved anticoagulant therapies with better safety and efficacy profiles.

Main Methods:

The content is based on presentations from a symposium titled 'Anticoagulation Strategies: Thrombin and Factor Xa Inhibition'.
Discussion of existing anticoagulants and emerging therapeutic targets.

Main Results:

Classical anticoagulants exhibit significant pharmacokinetic and safety drawbacks.
Novel anticoagulants are being developed to overcome the limitations of existing therapies.

Conclusions:

There is a clear need for new oral anticoagulants with improved properties.
Advances in inhibiting thrombin and Factor Xa represent a promising frontier in anticoagulation therapy.